Protagonist Therapeutics (PTGX) Interest Expenses (2015 - 2025)
Protagonist Therapeutics (PTGX) reported Interest Expenses of $501.3 million for Q4 2025, up 59507.61% on a YoY basis from N/an in Q4 2024, and up 59507.61% sequentially from $841000.0 in Q4 2024.
Protagonist Therapeutics (PTGX) Interest Expenses (2015 - 2025) Analysis & Trends
Protagonist Therapeutics (PTGX) has 11 years of Interest Expenses data on file, last reported at $501.3 million in Q4 2025.
- For the quarter ending Q4 2025, Interest Expenses rose 59507.61% year-over-year to $501.3 million; the trailing twelve-month figure through Dec 2025 stood at $501.3 million (up 85886.28% YoY), and the FY2025 full-year result was $501.3 million, up 227.86% from the prior year.
- Interest Expenses climbed to $501.3 million in Q4 2025, from $841000.0 in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $501.3 million in Q4 2025 to a low of -$1.6 million in Q4 2023.
- A 5-year average of $57.6 million and a median of $2.1 million in 2024 frame the typical range for Interest Expenses.
- Across the five-year window, Interest Expenses slumped 344.0% in 2023 and soared 59507.61% in 2025, its largest moves.
- Tracing PTGX's Interest Expenses over 5 years: stood at $556000.0 in 2021, then grew by 21.4% to $675000.0 in 2022, then sank by 344.0% to -$1.6 million in 2023, then soared by 151.06% to $841000.0 in 2024, then soared by 59507.61% to $501.3 million in 2025.
- Business Quant data shows PTGX's Interest Expenses at $501.3 million in Q4 2025, $841000.0 in Q4 2024, and $1.9 million in Q3 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -42,141.15 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 100,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 32.89 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 420.30 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 28.30 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 1.17 Bn |
| 10 | Protagonist Therapeutics | 8.88 Bn | 8.88 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 501.30 Mn |
| Dec 31, 2025 | 501.30 Mn |
| Dec 31, 2024 | 841,000.00 |
| Dec 31, 2024 | 841,000.00 |
| Sep 30, 2024 | 1.92 Mn |
| Sep 30, 2024 | 1.92 Mn |
| Jun 30, 2024 | 2.07 Mn |
| Jun 30, 2024 | 2.07 Mn |
| Mar 31, 2024 | 696,000.00 |
| Mar 31, 2024 | 696,000.00 |
| Dec 31, 2023 | -1.65 Mn |
| Dec 31, 2023 | -1.65 Mn |
| Sep 30, 2023 | 693,000.00 |
| Sep 30, 2023 | 693,000.00 |
| Jun 30, 2023 | 92.20 Mn |
| Jun 30, 2023 | 92.20 Mn |
| Mar 31, 2023 | 63.30 Mn |
| Mar 31, 2023 | 63.30 Mn |
| Dec 31, 2022 | 675,000.00 |
| Dec 31, 2022 | 675,000.00 |